Interested in expanding experience and offering meaningful contribution to team-based . All rights reserved. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX. Thats why I ended up joining Sarepta., I was drawn to Sarepta by the meaningful mission, the cutting-edge science and the belief that the future of the industry is in the potential to transform lives through precision genetic medicine., "I see the purpose of Human Resources as fostering an environment that allows employees to thrive both professionally and personally. These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). Learn more. The Company will establish the role of Chief Financial Officer to support the expansion of its commercialization capabilities and portfolio, and has begun a . What is health insurance like at Shape Therapeutics? Existing Subscriber? PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism Lorem ipsum dolor sit, amet consectetur adipisicing elit. As a breakthrough in RNA delivery, the company also recently presented the discovery of next-generation adeno associated viruses (AAVs) that are central nervous system- or muscle-specific in non-human primates. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Meet members of our executive team at StrideBio. As Doug noted, our full year net product revenue was $843.8 million . We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. cindy@shapetx.com, UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. Mark Velleca, M.D., Ph.D. > PRESIDENT AND CHIEF EXECUTIVE OFFICER Aravind Asokan, Ph.D. > FOUNDER AND ACTING CHIEF SCIENTIFIC OFFICER Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. focus on diversity and equityRead More. RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. Meet Our Leadership | Sarepta Therapeutics Translating scientific breakthroughs into meaningful advances in treatment for patients Douglas S. Ingram President and Chief Executive ReCode Therapeutics Strengthens Leadership Team With New Appointments - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC -. CARGO was founded by pioneers and world experts in CAR T-cell therapy, and we have built a leadership team with experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. Vice President of Finance, Gary Fortin GENEVA, DEC. 8, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare and ultra-rare disease areas on a global basis, today announced the appointments of Jack ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. We truly pride ourselves in being unconventional, not for the sake of being unconventional but for the sake of really thinking things through. ", I feel this real connection to the patients were having an impact on. Shape Therapeutics's key executives include David Huss and 11 others. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. ShapeTX is committed to data-driven scientific advancement, passionate people and a mission of providing life-long cures to patients. site you are consenting to these choices. You can read more about your cookie choices at our privacy policyhere. Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines to create a next generation precision oncology company. Founders Francois Vigneault, John Suliman, Prashant Mali. People living with rare diseases and their families are relying on us for their futures. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. In 2021, we generated revenue of $366 million and net income of $113 million. Get started with your Free Employer Profile, Work Here? This is a profile preview from the PitchBook Platform. The company closed a series B financing led by . Shape Therapeutics's is . 11 Shape Therapeutics reviews. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. All rights reserved. Company profile page for Shape Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information We will only send you email when there is any specific update about the company. A free inside look at company reviews and salaries posted anonymously by employees. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. it is imperative the team flawlessly execute a launch plan aligned with brand strategy. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Operating Status Active. | Source: The Head of Trade and Market Access will lead, develop, and execute on US and global, market access and pricing strategies working in close collaboration with the commercial leadership team and other leaders across the organization. Get the full list, Youre viewing 5 of 9 board members. Translating scientific breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy. Operator. Cindy Fung, PhD All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. Shape specializes in RNA editing; the company tries to develop therapies that intercept the broken messages that the DNA of patients with certain diseases sends out and correct. Im thrilled to join such a talented team of innovative thinkers. Get the full list, Youre viewing 5 of 10 investors. Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. Great team culture. Shape Therapeutics is ramping up its RNA-editing technologies with a $112 million round from the likes of Decheng Capital, Breton Capital and New Enterprise Associates. Shape Therapeutics CEO, Founder, Key Executive Team, Board of Directors & Employees Annemieke Aartsma-Rus, PhD was elected to our Scientific Advisory Board in November 2019. Legal Name Shape Therapeutics, Inc. Company Type For Profit. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. We have plenty of data and we can help. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Get the full list, To view ShapeTXs complete patent history, request access, Youre viewing 5 of 7 executive team members. Boston, MA 02111. Powered by Madgex Job Board Software. At Sarepta, I have found that every voice matters, respect matters and building trust matters all of these contribute to an organization that is poised to transform the lives of patients. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Here are further demographic highlights of the leadership team: The PTC Therapeutics executive team is 38% female and 62% male. Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observedSOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NE. With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. ", "Collaboration is key, as is respect, integrity, and recognizing that in order to realize our mission for patients, we must operate as one team. - Pharmacovigilance / Product Lifecycle Management - Technology / Data / Analytics - Clinical Biostatistics and Programming - Clinical Trial Monitoring - Data Management - Overview - Packaging In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. Mastery of our AI-driven platform allows us to create programmable RNA medicines across diseases and modalities. ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. . Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. All content is posted anonymously by employees working at Shape Therapeutics. Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. Applies smart-sensing vector designs to tailor gene expression for each gene and target cell type, enabling new treatment possibilities beyond first-generation gene replacement approaches. ShapeTX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. cindy@shaptetx.com, 1985 - 2023 BioSpace.com. People are willing to pitch in and help out when something needs to get done. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. Chief Business Officer, Will Krause No credit card required. You can read more about your. Chief Scientific Officer, Francois Vigneault Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Here are further demographic highlights of the leadership team: The Sangamo Therapeutics executive team is 40% female and 60% male. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. {{ userNotificationState.getAlertCount('bell') }}. Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. CBI websites generally use certain cookies to enable better interactions with our sites and services. In his new role as CSO, Dr. Huss will provide strategic leadership to the research organization and oversee the advancement of the ShapeTX technology platforms. PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. Its very rewarding. We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. Interested in what they do or partnership? Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). Shape Therapeutics's founder is Prashant Mali. Lead investor BRV Capital Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st. Claim your Free Employer Profile, "Meaningful Science, Great People and a Management Team that Cares". | Source: The ShapeTX platform combines AI and RNA technology to discover and design new medicines that will be effective, safe and easy to manufacture. Also Known As ShapeTX. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. We deploy the ShapeTX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Interested in researching Shape Therapeutics? Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . ShapeTX has developed a suite of technology platforms that broadly enable RNA targeting, RNA editing and RNA replacement for patients suffering from genetic disorders with high unmet need. Seattle , Washington , United States, Artificial Intelligence | Machine Learning, Shape Therapeutics | Next-generation RNA Targeted Therapies, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism. Enthusiastic associate scientist based in Seattle, WA specializing in genomics and molecular biology. Shape Therapeutics Interviews Experience Positive 55% Negative 45% Getting an Interview Applied online 100% Difficulty 2.7 Average Hard Average Easy Sep 1, 2022 Research Associate/ Sr. RA/ Assoc. 2023 PitchBook. Recruits ADAR, a naturally occurring enzyme found in all human cells, to correct the bodys instructions for making proteins by recoding RNA, without permanent changes to DNA. Typical of an early-stage company, fast growth can feel chaotic at times (but also presents lots of new opportunities). The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. Shape Therapeutics, Inc. employs 14 employees. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? David Huss Vice President, Head of Research Francois Vigneault President and CEO Gary Fortin Chief Operating Officer (COO) John Suliman CFO & Head of Business Strategy Ken Prentice A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . CBI websites generally use certain cookies to enable better interactions with. Discover current leadership team members including founders, CEO, other executives and board directors. Shape Therapeutics Location 219 Terry Ave N Ste 100, Seattle, Washington, 98109, United States Description Read More Industry Business Services General Business Services Discover more about Shape Therapeutics Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer 11 Shape Therapeutics reviews. Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the . Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. Claim your profile to get in front of buyers, investors, and analysts. Shape Life! Shape Therapeutics Inc. Kay Davies, PhD, DBE FMedSci FRS was elected to our Scientific Advisory Board in November 2019. Shape Therapeutics has 5 executives. Headquarters Location 219 Terry Ave N Suite 100 Rznomics was founded in 2017 and is based in Yongin-si, South Korea. We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases.. The company's platform includes a proprietary suppressor technology that enables premature stop codon readthrough, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs, enabling patients with lifelong cures. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. I cannot imagine being anyplace else.". We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. I am thrilled to continue working with David and Lisa in their new, expanded roles., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. So far, I like the team. At this time, all participants are in a listen-only mode . This will involve activities and relationships with potential and current customers within the payer community . Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. Lorem ipsum dolor sit amet consectetur adipisicing elit. She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). There isnt a path to guide us. This is the Shape Therapeutics company profile. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? Our deal sourcing platform can help you perform more research about Shape Therapeutics, David Huss Last Funding Type Series B. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, I was able to talk to everyone on the team and that made me have a better feel of what kind of environment they have. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Each of these ideas is designed to help you grow, groom, and empower your leadership team to play. And I thought, imagine how Ill feel if we can reach more kids. Explore {Shape Therapeutics's key management people. Contact Information Website www.shapetx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 219 Terry Avenue North Suite 100 Seattle, WA 98109 United States +1 (628) 000-0000 ShapeTX Timeline 2020 2021 2022 2023 Shape Life! ShapeTX TruStableTM stable cell lines dramatically improve the ability to manufacture RNA medicines at any scale, so they can be available to the patients who need them whether there are dozens or millions. Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Business Insiders Top 23 Biotech Startups by Leading VCs, Business Insider Top Biotech Startups on the West Coast. 219 Terry Avenue North Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy@shaptetx.com. We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswapTM payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. beam therapeutics durham address By Feb 26, 2023 info@beamtx.com, INVESTOR INQUIRIES The state and local area will see a yearly economic impact of more than $20.6 million from this companys new payroll. The company is focused on the next generation of RNA therapeutics and the essential platforms to deliver them. We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. million verified professionals across 35 million companies. Enter employee name to find & verify emails, phones, social links, etc. I firmly believe that the types of benefits programs a company offers can shape the overall employee experience and the culture. They seem respectful towards one another. 69% of the management team is White. Shape Therapeutics is . Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. free lookups / month. CAR T-cell therapy to overcome. Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. Investors & Media Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Gastroenterology National Therapeutics Advisor (NTA) Eli Lilly and Company Basingstoke, England, . Shape Life! Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's,. Shape Therapeutics's Vice President, Head of Research is David Huss. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. Do you excel more in a team or individual setting? Engineering best-in-class. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients.
Do You Capitalize The Word Grace?,
Reveal Algebra 1, Volume 1 Answer Key,
Ali Macgraw Grandchildren,
Articles S